---
schema_version: "secwatch.filing_event.v1"
accession: "0001213900-23-037951"
form_type: "8-K"
ticker: "BJDX"
cik: "0001704287"
company_name: "Bluejay Diagnostics, Inc."
filed_at: "2023-05-10T23:59:59+00:00"
generated_at: "2026-06-15T06:37:16.077173+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.4
calibrated_materiality_score: 0.4
confidence: "high"
source: SEC EDGAR
---

# Bluejay Diagnostics Q1 net loss $2.5M, cash $6.8M; focuses on FDA pathway

## Summary
- Net loss of $2.5M ($0.12/shr) vs $2.0M ($0.10/shr) in Q1 2022.
- Cash and equivalents fell to $6.8M at March 31, 2023 from $10.1M at Dec 31, 2022.
- R&D expense rose to $1.4M from $695k, driven by clinical trial and personnel costs.
- CEO notes resources aligned with FDA feedback to optimize Symphony IL-6 approval pathway.
- No revenue reported; pre-commercial stage diagnostics company.

## SEC filing metadata
- accession: 0001213900-23-037951
- form_type: 8-K
- ticker: BJDX
- cik: 0001704287
- company_name: Bluejay Diagnostics, Inc.
- filed_at: 2023-05-10T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.4
- calibrated_materiality_score: 0.4
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1704287/000121390023037951/0001213900-23-037951-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1704287/000121390023037951/ea178223-8k_bluejay.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001213900-23-037951
- JSON: https://secwatch.observer/filing/0001213900-23-037951.json
- Plain text: https://secwatch.observer/filing/0001213900-23-037951.txt

## Key facts
- Earnings Releases
  Bluejay Diagnostics, Inc. reported quarter ended March 31, 2023 results: net income $2.5 million, or $0.12 per share, EPS $0.12 per share.
  - Period: quarter ended March 31, 2023
  - Net income: $2.5 million, or $0.12 per share
  - EPS: $0.12 per share
  - Result: reported results
  source text: The net loss was $2.5 million, or $0.12 per share for the three months ended March 31, 2023, compared to $2.0 million, or $0.10 per share, for the comparable period in 2022.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1704287/000121390023037951/0001213900-23-037951-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.